News Release

Yamanouchi Pharmaceutical Co., Ltd.

Yamanouchi Sale of Shire Pharmaceutical Stake

September 26, 2000

Tokyo - September 26, 2000 --- Yamanouchi Group Holding Inc. (YGH), a U.S. subsidiary of Yamanouchi Pharmaceutical Co., Ltd., (Yamanouchi: Toichi Takenaka, President and CEO), agreed to sell to Bear, Stearns & Co. Inc. in an underwritten transaction all of its American Depositary Shares (ADSs)* of Shire Pharmaceutical Group plc, of the U.K. on September 25, 2000, Eastern Daylight Time in the U.S. The total number of ADSs sold was 5,263,902. As a result of this transaction, Yamanouchi will report approximately 10 billion Japanese yen gain on sales of investment securities in Yamanouchi's consolidated statement of income.

Yamanouchi group made a strategic investment in Roberts Pharmaceutical Corporation of the U.S. in March 1992 as one of the options to expand its pharmaceutical operation in the U.S., and both companies proceeded to build a collaborative relationship. In December 1999, YGH became an approximately 6.5% shareholder of Shire as a result of the Shire-Roberts merger. YGH has sold its entire stake in Shire because of a recent strategic decision by Yamanouchi with respect to the U.S. market; Yamanouchi will strengthen its U.S. business through its U.S. subsidiaries.

Written prospectuses in connection with the transaction will be delivered by Bear, Stearns & Co. Inc., 245 Park Ave., New York, NY10167.

* ADSs: American Depositary Shares
Shares issued under a deposit agreement representing the underlying ordinary shares of the issuer that trades in the issuer's home market.

<Shire Pharmaceutical Group plc.>
Founded: 1986
Headquarters: Hampshire, England
Representative: Rolf Stahel, Chief Executive
Sales: $401.5 million (1999)
Employees: 1,010 (as of 1999)
Business: Mainly from sales of pharmaceutical products.